

Konstantinos N Lazaridis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2603951/publications.pdf>

Version: 2024-02-01

114
papers

7,640
citations

87843

38
h-index

54882

84
g-index

122
all docs

122
docs citations

122
times ranked

10508
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2594-2599.	1.1	4
2	Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation. <i>Hepatology Communications</i> , 2022, 6, 345-360.	2.0	12
3	High-Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. <i>Hepatology Communications</i> , 2022, 6, 965-979.	2.0	11
4	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis. , 2022, 1, 287-295.		1
5	Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. <i>Genetics in Medicine</i> , 2022, 24, 1062-1072.	1.1	28
6	DNA methylation profile of liver tissue in end-stage cholestatic liver disease. <i>Epigenomics</i> , 2022, 14, 481-497.	1.0	2
7	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. <i>Hepatology</i> , 2021, 74, 281-295.	3.6	40
8	Impact of integrated translational research on clinical exome sequencing. <i>Genetics in Medicine</i> , 2021, 23, 498-507.	1.1	24
9	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1868-1881.	3.6	25
10	Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. <i>BMC Gastroenterology</i> , 2021, 21, 149.	0.8	3
11	Environmental risk factors are associated with autoimmune hepatitis. <i>Liver International</i> , 2021, 41, 2396-2403.	1.9	10
12	Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1407-1417.	1.4	6
13	Genomics Integration Into Nephrology Practice. <i>Kidney Medicine</i> , 2021, 3, 785-798.	1.0	13
14	Discovery and Opportunities With Integrative Analytics Using Multiple-Omics Data. <i>Hepatology</i> , 2021, 74, 1081-1087.	3.6	3
15	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
16	A scalable workflow to characterize the human exposome. <i>Nature Communications</i> , 2021, 12, 5575.	5.8	31
17	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2342-2353.	1.4	20
18	The PSC scientific community resource: an asset for multi-omics interrogation of primary sclerosing cholangitis. <i>BMC Gastroenterology</i> , 2021, 21, 353.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Nine-gene pharmacogenomics profile service: The Mayo Clinic experience. <i>Pharmacogenomics Journal</i> , 2021, , .	0.9	13
20	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. <i>Hepatology</i> , 2020, 71, 214-224.	3.6	90
21	Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases. <i>Hepatology</i> , 2020, 71, 352-362.	3.6	18
22	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1576-1583.e1.	2.4	30
23	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
24	Genome-wide resolution peripheral blood methylome profiling reveals signatures for cholestatic liver disease. <i>Epigenomics</i> , 2020, 12, 1363-1375.	1.0	3
25	Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. <i>Blood Cancer Journal</i> , 2020, 10, 120.	2.8	2
26	Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. <i>Scientific Reports</i> , 2020, 10, 12584.	1.6	13
27	A predictive index for health status using species-level gut microbiome profiling. <i>Nature Communications</i> , 2020, 11, 4635.	5.8	129
28	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. <i>Future Science OA</i> , 2020, 6, FSO441.	0.9	8
29	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. <i>Journal of Gastroenterology</i> , 2020, 55, 523-532.	2.3	22
30	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1753-1768.	1.4	21
31	Individualized medicine comes to the liver clinic. <i>Journal of Hepatology</i> , 2019, 70, 1057-1059.	1.8	9
32	Cell-free DNA testing: future applications in gastroenterology and hepatology. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984189.	1.4	7
33	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
34	<scp>PACE</scp> Forwardâ€Making Pharmacogenomics Testing Available for Realâ€Life Clinical Utility. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 42-44.	2.3	3
35	PNPLA3 Association with Alcoholic Liver Disease in a Cohort of Heavy Drinkers. <i>Alcohol and Alcoholism</i> , 2018, 53, 357-360.	0.9	13
36	Primary biliary cholangitis, DNA, and beyond: The Relative contribution of genes. <i>Hepatology</i> , 2018, 68, 19-21.	3.6	5

#	ARTICLE	IF	CITATIONS
37	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
38	Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3188.	1.8	28
39	External validation of the United Kingdomâ€primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018, 2, 676-682.	2.0	6
40	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
41	Variations in primary sclerosing cholangitis across the age spectrum. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1763-1768.	1.4	18
42	Emerging pharmacologic therapies for primary sclerosing cholangitis. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 149-157.	1.0	14
43	Preemptive sequencing in the genomic medicine era. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 91-98.	0.4	3
44	Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 651-652.	1.8	1
45	Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 269-279.	0.6	30
46	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2017, 37, 159-174.	1.8	26
47	Improving Therapeutic Odyssey: Preemptive Pharmacogenomics Utility in Patient Care. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 39-41.	2.3	12
48	Clinical characteristics and platelet phenotype in a family with <i>RUNX1</i> mutated thrombocytopenia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1963-1967.	0.6	10
49	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
50	The prevalence of diseases caused by lysosome-related genes in a cohort of undiagnosed patients. <i>Molecular Genetics and Metabolism Reports</i> , 2017, 13, 46-51.	0.4	17
51	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	0.8	55
52	Individualized Medicine in Gastroenterology and Hepatology. <i>Mayo Clinic Proceedings</i> , 2017, 92, 810-825.	1.4	10
53	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 26245-26255.	0.8	14
54	Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. <i>Oncotarget</i> , 2016, 7, 54526-54536.	0.8	85

#	ARTICLE	IF	CITATIONS
55	Low incidence of primary biliary cirrhosis (<scp>PBC</scp>) in the first-degree relatives of <scp>PBC</scp> probands after 8 years of follow-up. Liver International, 2016, 36, 1378-1382.	1.9	22
56	Performance of magnetic resonance elastography in primary sclerosing cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1184-1190.	1.4	83
57	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 2500-2502.	13.9	48
58	Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. American Journal of Gastroenterology, 2016, 111, 705-711.	0.2	88
59	Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent. Gastrointestinal Endoscopy, 2016, 84, 950-958.e3.	0.5	7
60	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 1161-1170.	13.9	358
61	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Scientific Reports, 2016, 6, 25.	1.6	32
62	Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics, 2016, 48, 510-518.	9.4	617
63	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. Mayo Clinic Proceedings, 2016, 91, 297-307.	1.4	83
64	Genome-Wide Association Studies in Primary Biliary Cirrhosis. Seminars in Liver Disease, 2015, 35, 392-401.	1.8	59
65	Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. Cancer Medicine, 2015, 4, 1599-1602.	1.3	9
66	Biliary Multifocal Chromosomal Polysomy and Cholangiocarcinoma in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2015, 110, 299-309.	0.2	51
67	Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential. Gastrointestinal Endoscopy, 2015, 82, 550-556.e1.	0.5	7
68	Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 143, 879-888.	0.4	40
69	The Cholangiopathies. Mayo Clinic Proceedings, 2015, 90, 791-800.	1.4	167
70	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nature Communications, 2015, 6, 8019.	5.8	245
71	A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 980-990.	1.9	50
72	Kinase Genotype Analysis of Gastric Gastrointestinal Stromal Tumor Cytology Samples Using Targeted Next-Generation Sequencing. Clinical Gastroenterology and Hepatology, 2015, 13, 202-206.	2.4	28

#	ARTICLE	IF	CITATIONS
73	Characterization of Endoscopic Ultrasound Fine-Needle Aspiration Cytology by Targeted Next-Generation Sequencing and Theranostic Potential. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 37-41.	2.4	27
74	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	1.5	292
75	Environmental Factors in Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 265-272.	1.8	64
76	Novel de novo heterozygous <i>FGFR1</i> mutation in two siblings with Hartsfield syndrome: A case of gonadal mosaicism. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 2356-2359.	0.7	17
77	Implementing individualized medicine into the medical practice. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 15-23.	0.7	58
78	Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1414-1420.	2.3	35
79	Reduced Coffee Consumption Among Individuals With Primary Sclerosing Cholangitis but Not Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1562-1568.	2.4	38
80	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 718-721.	1.4	15
81	Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. <i>Gastroenterology</i> , 2013, 145, 521-536.	0.6	359
82	The Genetics of Complex Cholestatic Disorders. <i>Gastroenterology</i> , 2013, 144, 1357-1374.	0.6	126
83	Questionnaire based assessment of risk factors for primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2013, 45, 589-594.	0.4	38
84	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
85	ImmunoChIP analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	1.4	139
86	Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. <i>Liver International</i> , 2011, 31, 785-791.	1.9	21
87	Ulcerative colitis and an abnormal cholangiogram. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 306-311.	0.6	0
88	Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: Evidence for a gene-gene interaction. <i>Hepatology</i> , 2010, 52, 223-229.	3.6	36
89	Emerging genes associated with the progression of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 807-811.	3.6	12
90	Primary biliary cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 647-654.	1.0	32

#	ARTICLE	IF	CITATIONS
91	Update on the genetics and genomics of PBC. <i>Journal of Autoimmunity</i> , 2010, 35, 181-187.	3.0	31
92	Common Genetic Variation and Haplotypes of the Anion Exchanger SLC4A2 in Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1406-1411.	0.2	20
93	Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants. <i>New England Journal of Medicine</i> , 2009, 360, 2544-2555.	13.9	569
94	Sclerosing Cholangitis Epidemiology and Etiology. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 417-419.	0.9	13
95	Primary Biliary Cirrhosis Is Associated With a Genetic Variant in the 3' Flanking Region of the CTLA4 Gene. <i>Gastroenterology</i> , 2008, 135, 1200-1206.	0.6	62
96	Genetics and Genomics of Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2008, 12, 349-365.	1.0	23
97	Applying Genomics to the Study of Complex Disease. <i>Seminars in Liver Disease</i> , 2007, 27, 003-012.	1.8	12
98	Clinical Epidemiology of Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 494-500.	1.1	58
99	Our New President—Nicholas F. LaRusso, MD. <i>Gastroenterology</i> , 2007, 132, 2005-2011.	0.6	2
100	Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. <i>Hepatology</i> , 2007, 46, 785-792.	3.6	125
101	Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. <i>Hepatology</i> , 2007, 47, 563-570.	3.6	44
102	Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. <i>Hepatology</i> , 2007, 47, 8-10.	3.6	6
103	Polluting the pathogenesis of primary biliary cirrhosis. <i>Hepatology</i> , 2006, 43, 398-400.	3.6	6
104	Genomics and complex liver disease: Challenges and opportunities. <i>Hepatology</i> , 2006, 44, 1380-1390.	3.6	28
105	Primary Sclerosing Cholangitis and Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2006, 26, 042-051.	1.8	123
106	Genomics, genetic epidemiology, and genomic medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 320-328.	2.4	8
107	Hematological malignancy manifesting as ascites. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 112-116.	1.7	4
108	Cholangiocarcinoma. <i>Gastroenterology</i> , 2005, 128, 1655-1667.	0.6	417

#	ARTICLE	IF	CITATIONS
109	American Gastroenterological Association Future Trends Committee Report: The Application of Genomic and Proteomic Technologies to Digestive Disease Diagnosis and Treatment and Their Likely Impact on Gastroenterology Clinical Practice. <i>Gastroenterology</i> , 2005, 129, 1720-1752.	0.6	17
110	The cholangiopathies: Disorders of biliary epithelia. <i>Gastroenterology</i> , 2004, 127, 1565-1577.	0.6	326
111	Bile formation: Do not ignore the role of plasma membrane-cytoskeleton linking proteins. <i>Hepatology</i> , 2003, 37, 218-220.	3.6	5
112	Ursodeoxycholic acid – mechanisms of action and clinical use in hepatobiliary disorders™. <i>Journal of Hepatology</i> , 2001, 35, 134-146.	1.8	354
113	Management of primary biliary cirrhosis: From diagnosis to end-stage disease. <i>Current Gastroenterology Reports</i> , 2000, 2, 94-98.	1.1	5
114	Primary biliary cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 473-480.	0.3	3